Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | PYGB | P11216 | 1/20 | 0.33 |
| ▸ | ADK | P55263 | 3/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | SELP | P16109 | 2/20 | 0.31 |
| ▸ | SELL | P14151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18654184 | 1.00 | OGA (0.39) | OGAFUCA1FBP1PYGBADK | |
| SCHEMBL14477812 | 1.00 | OGA (0.39) | OGAFUCA1FBP1PYGBADK | |
| SCHEMBL15258019 | 1.00 | OGA (0.39) | OGAFUCA1FBP1PYGBADK | |
| SCHEMBL16645339 | 1.00 | OGA (0.39) | OGAFUCA1FBP1PYGBADK | |
| SCHEMBL16645340 | 1.00 | OGA (0.39) | OGAFUCA1FBP1PYGBADK | |
| SCHEMBL17254899 | 1.00 | OGA (0.39) | OGAFUCA1FBP1PYGBADK | |
| SCHEMBL18654333 | 1.00 | OGA (0.39) | OGAFUCA1FBP1PYGBADK | |
| SCHEMBL16645296 | 1.00 | OGA (0.39) | OGAFUCA1FBP1PYGBADK | |
| SCHEMBL24323044 | 0.98 | OGA (0.40) | OGAFUCA1FBP1PYGBADK | |
| SCHEMBL12899827 | 0.98 | OGA (0.40) | OGAFUCA1FBP1PYGBADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160022794-A1 | SIDEROPHORE-BASED IMMUNIZATION AGAINST GRAM-NEGATIVE BACTERIA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2015168380-A1 | SIDEROPHORE-BASED IMMUNIZATION AGAINST GRAM-NEGATIVE BACTERIA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015057958-A2 | ENTEROBACTIN CONJUGATES AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20150105337-A1 | ENTEROBACTIN CONJUGATES AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105337-A1 | ENTEROBACTIN CONJUGATES AND USES THEREOF | BTD, VIP, SLC10A2 | OGA 2873/4885FUCA1 426/4885FBP1 1123/4885 |
| US-20160022794-A1 | SIDEROPHORE-BASED IMMUNIZATION AGAINST GRAM-NEGATIVE BACTERIA | SLC40A1, SFXN1, SLC75A1 | OGA 2484/4885FUCA1 704/4885FBP1 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.